Abstract: Objective: To study the effect of Omazzo monoclonal antibody plus glucocorticoid on symptoms and pulmonary function in patients with allergic asthma. Methods: 2013 June 2014 in June from 56 cases of allergic asthma patients as the research object, according to the needs, were randomly divided to observation group and control group, 26 cases of control group with the implementation of appropriate glucocorticoid therapy. 30 cases of observation group were treated with Omazzo monoclonal antibody and glucocorticoid therapy, and the change of pulmonary function indexes and curative effect were compared between the 2 groups. Results: the combination of the subsequent statistical analysis, it shows that, compared with before treatment, treatment in the two groups after the peak expiratory flow (PEF), timed vital capacity of the first second (FEV1) and V25% one of the 75% and other indicators improved significantly (P < 0.05), compared to control group, apparently to observe the indexes of lung function group improved more obviously (P < 0.05), in the total effective rate of treatment in the two groups, the observation group was significantly higher than that of the control group (P < 0.05). Conclusion: according to the results, in the treatment of allergic asthma patients, compared to single glucocorticoid treatment, Omazzo monoclonal antibody (McAb) with glucocorticoid therapy to improve the pulmonary function in patients with more obvious, with the higher safety, should be recommended.